This is an aggregated industry headline. Read the full story at FierceBiotech →
AstraZeneca unveils phase 3 bone disease data behind $5B forecast for Strensiq successor
AstraZeneca has shared the data behind previously disclosed phase 3 rare disease wins, fleshing out the case for a Strensiq successor tipped to generate blockbuster sales. The company has yet to share data from a third trial that missed its primary endpoint.
By FierceBiotech
· Jun 29, 2026
· via FierceBiotech
Image: FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
As Amgen prepares to defend Tavneos' market approval in the U.S., the company has received a bad omen overseas…
The WeekBriefing
STAT News flagged two developments: a congressional bill to revamp the 340B drug discount program and talk of …
The WeekSTAT News ↗
In a Q&A, Kenneth Chien, no longer with Moderna, predicts the company's mRNA cancer vaccine will be transforma…